InvestSMART

Neuren Pharmaceuticals Limited (ASX: NEU) - Announcements

Current share price for NEU : $20.200 0.23 (1.13%)+

ASX company news and announcements for Neuren Pharmaceuticals Limited (NEU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neuren Pharmaceuticals Limited (NEU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neuren Pharmaceuticals Limited (NEU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neuren Pharmaceuticals Limited (NEU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,561 Notification of cessation of securities - NEU 3 Mar 2025 5:20PM $13.210 $20.200 risen by 52.91%
$2,561 2024 Full Year Results webinar 28 Feb 2025 12:10PM $13.530 $20.200 risen by 49.30%
$2,561 Neuren receives DAYBUE sales milestone payment of US$50m 28 Feb 2025 11:45AM $13.480 $20.200 risen by 49.85%
$2,561 2024 results - A$166m comprehensive income for shareholders 28 Feb 2025 9:35AM $14.200 $20.200 risen by 42.25%
$2,561 Appendix 4E and 2024 full year accounts 28 Feb 2025 9:28AM $14.200 $20.200 risen by 42.25%
$2,561 Neuren 2024 results investor webinar on 28 February 2025 27 Feb 2025 10:24AM $13.750 $20.200 risen by 46.91%
$2,561 DAYBUE (trofinetide) 2024 net sales US$348 million 27 Feb 2025 10:01AM $13.040 $20.200 risen by 54.91%
$2,561 Becoming a substantial holder 25 Feb 2025 7:30AM $13.810 $20.200 risen by 46.27%
$2,561 Neuren receives Rare Pediatric Disease Designation from FDA 24 Feb 2025 9:19AM $13.270 $20.200 risen by 52.22%
$2,561 Fast Track granted by FDA for NNZ-2591 in Pitt Hopkins 19 Feb 2025 1:00PM $13.300 $20.200 risen by 51.88%
$2,561 Priority Review Voucher sale proceeds received 7 Feb 2025 12:03PM $13.980 $20.200 risen by 44.49%
$2,561 Type C Meeting granted by FDA for Phelan-McDermid syndrome 7 Feb 2025 8:14AM $13.930 $20.200 risen by 45.01%
$2,561 Neuren to present at autism research meeting 6 Feb 2025 9:09AM $13.760 $20.200 risen by 46.80%
$2,561 NEU Presentations at ACMG Annual Clinical Genetics Meeting 22 Jan 2025 8:22AM $13.600 $20.200 risen by 48.53%
$2,561 J.P. Morgan Healthcare Conference recap 20 Jan 2025 10:14AM $13.270 $20.200 risen by 52.22%
$2,561 Neuren JP Morgan Healthcare Conference 2025 presentation 16 Jan 2025 10:26AM $11.620 $20.200 risen by 73.84%
$2,561 Trofinetide marketing application submitted in Europe 15 Jan 2025 9:26AM $12.000 $20.200 risen by 68.33%
$2,561 Update - Notification of buy-back - NEU 18 Dec 2024 8:51AM $13.160 $20.200 risen by 53.50%
$2,561 Update - Notification of buy-back - NEU 17 Dec 2024 8:53AM $13.300 $20.200 risen by 51.88%
$2,561 Update - Notification of buy-back - NEU 16 Dec 2024 9:13AM $13.320 $20.200 risen by 51.65%
$2,561 Update - Notification of buy-back - NEU 13 Dec 2024 8:55AM $13.240 $20.200 risen by 52.57%
$2,561 Priority Review Voucher sale complete 12 Dec 2024 9:31AM $13.440 $20.200 risen by 50.30%
$2,561 Update - Notification of buy-back - NEU 12 Dec 2024 9:04AM $13.440 $20.200 risen by 50.30%
$2,561 Update - Notification of buy-back - NEU 11 Dec 2024 9:35AM $12.970 $20.200 risen by 55.74%
$2,561 Update - Notification of buy-back - NEU 10 Dec 2024 9:12AM $12.740 $20.200 risen by 58.56%

176 - 200 of 833 results

Page 8 of 34

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.